Unlike sulfonylureas or insulin, which are associated with higher rates of hypoglycemia, DPP-4 inhibitors such as alogliptin generally exhibit a low risk of hypoglycemia, and this was observed in the EXAMINE trial as well. This evidence concerns the gene DPP4 and Hypoglycemia.